antiviral and associated therapy for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. anti-inflammatoty and immuno-therapy
vs. Immunostimulants drugs
vs. interferon
vs. Immunosuppressants drugs
vs. anti-interleukin-6
vs. tocilizumab
vs. antiviral and associated therapy
vs. azithromycin
vs. chloroquine and derivatives
vs. chloroquine
vs. hydroxychloroquine
vs. favipiravir
vs. hydroxychloroquine plus macrolides
vs. lopinavir/ritonavir
vs. remdesivir
vs. ribavirin
vs. umifenovir (arbidol)
vs. control
vs. placebo
vs. standard of care
vs. Vitamins
vs. vitamin C

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 4

table network network 2

display ongoing demontrated benefit only

click on circles to display study description...

Tricou, 2010

chloroquine and derivatives (n=278) vs. placebo (n=276)

randomized controlled trial

Studied treatment

600 mg D1-2, 300 mg D3

Control treatment

placebo

Patients

infections other than COVID-19

Method

double-blind

Viet Nam

Remark

Borges, 2013

chloroquine and derivatives (n=63) vs. placebo (n=66)

randomized controlled trial

Studied treatment

chloroquine 600 mg/day for three days

Control treatment

placebo

Patients

infections other than COVID-19

Method

Brazil

Remark

Paton, 2011 NCT01078779

chloroquine and derivatives (n=757) vs. placebo (n=749)

randomized controlled trial

Studied treatment

chloroquine
chloroquine phosphate (500 mg/day for 1 week, then once a week to complete 12 weeks)

Control treatment

placebo

Patients

infections other than COVID-19

Method

double-blind

Singapore

Remark

powered by vis.js Network

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open